Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
83 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Influenza B Infections - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Influenza B Infections - Pipeline Review, H1 2016', provides an overview of the Influenza B Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Influenza B Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Influenza B Infections and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Influenza B Infections - The report reviews pipeline therapeutics for Influenza B Infections by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Influenza B Infections therapeutics and enlists all their major and minor projects - The report assesses Influenza B Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Influenza B Infections Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Influenza B Infections - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Influenza B Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Influenza B Infections Overview 9 Therapeutics Development 10 Pipeline Products for Influenza B Infections - Overview 10 Pipeline Products for Influenza B Infections - Comparative Analysis 11 Influenza B Infections - Therapeutics under Development by Companies 12 Influenza B Infections - Therapeutics under Investigation by Universities/Institutes 14 Influenza B Infections - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Influenza B Infections - Products under Development by Companies 18 Influenza B Infections - Products under Investigation by Universities/Institutes 19 Influenza B Infections - Companies Involved in Therapeutics Development 20 Altravax, Inc. 20 Aphios Corporation 21 Chimerix, Inc. 22 ContraFect Corporation 23 Crucell N.V. 24 CSL Limited 25 Genentech, Inc. 26 Hanmi Pharmaceuticals, Co. Ltd. 27 Humabs BioMed SA 28 Medicago Inc. 29 MedImmune, LLC 30 Mucosis B.V. 31 Novavax, Inc. 32 Sanofi Pasteur SA 33 Vaxart, Inc. 34 Zydus Cadila Healthcare Limited 35 Influenza B Infections - Therapeutics Assessment 36 Assessment by Monotherapy Products 36 Assessment by Combination Products 37 Assessment by Target 38 Assessment by Mechanism of Action 40 Assessment by Route of Administration 42 Assessment by Molecule Type 44 Drug Profiles 46 AL-18 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 APP-0205 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 APP-309 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 CF-403 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 CR-8033 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 CR-8071 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 CR-9114 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 FluGEM - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 influenza [serotype B] vaccine - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 influenza [serotypes A, B] (split virion, tetravalent) vaccine - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (tetravalent, split virion) vaccine - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent, virus like particle) vaccine - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 Monoclonal Antibody for Influenza B Infections - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 oseltamivir phosphate - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 RG-6024 - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 Small Molecules for Influenza B - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 VXABYW-10 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 Influenza B Infections - Recent Pipeline Updates 74 Influenza B Infections - Dormant Projects 79 Influenza B Infections - Product Development Milestones 80 Featured News & Press Releases 80 Dec 17, 2015: Vaxart Announces Enrollment of First Patient in Influenza B Phase 1 Trial 80 Mar 11, 2011: Sanofi Pasteur And Daiichi Sankyo Announce Voluntary Recall Of Hemophilus Influenza Type B Conjugate Vaccine 81 Apr 23, 1993: FDA Approval of Use of a New Haemophilus b Conjugate Vaccine and a Combined Diphtheria-Tetanus-Pertussis and Haemophilus b Conjugate Vaccine for Infants and Children 81 Appendix 82 Methodology 82 Coverage 82 Secondary Research 82 Primary Research 82 Expert Panel Validation 82 Contact Us 82 Disclaimer 83
List of Tables Number of Products under Development for Influenza B Infections, H1 2016 10 Number of Products under Development for Influenza B Infections - Comparative Analysis, H1 2016 11 Number of Products under Development by Companies, H1 2016 13 Number of Products under Investigation by Universities/Institutes, H1 2016 14 Comparative Analysis by Late Stage Development, H1 2016 15 Comparative Analysis by Clinical Stage Development, H1 2016 16 Comparative Analysis by Early Stage Development, H1 2016 17 Products under Development by Companies, H1 2016 18 Products under Investigation by Universities/Institutes, H1 2016 19 Influenza B Infections - Pipeline by Altravax, Inc., H1 2016 20 Influenza B Infections - Pipeline by Aphios Corporation, H1 2016 21 Influenza B Infections - Pipeline by Chimerix, Inc., H1 2016 22 Influenza B Infections - Pipeline by ContraFect Corporation, H1 2016 23 Influenza B Infections - Pipeline by Crucell N.V., H1 2016 24 Influenza B Infections - Pipeline by CSL Limited, H1 2016 25 Influenza B Infections - Pipeline by Genentech, Inc., H1 2016 26 Influenza B Infections - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016 27 Influenza B Infections - Pipeline by Humabs BioMed SA, H1 2016 28 Influenza B Infections - Pipeline by Medicago Inc., H1 2016 29 Influenza B Infections - Pipeline by MedImmune, LLC, H1 2016 30 Influenza B Infections - Pipeline by Mucosis B.V., H1 2016 31 Influenza B Infections - Pipeline by Novavax, Inc., H1 2016 32 Influenza B Infections - Pipeline by Sanofi Pasteur SA, H1 2016 33 Influenza B Infections - Pipeline by Vaxart, Inc., H1 2016 34 Influenza B Infections - Pipeline by Zydus Cadila Healthcare Limited, H1 2016 35 Assessment by Monotherapy Products, H1 2016 36 Assessment by Combination Products, H1 2016 37 Number of Products by Stage and Target, H1 2016 39 Number of Products by Stage and Mechanism of Action, H1 2016 41 Number of Products by Stage and Route of Administration, H1 2016 43 Number of Products by Stage and Molecule Type, H1 2016 45 Influenza B Infections Therapeutics - Recent Pipeline Updates, H1 2016 74 Influenza B Infections - Dormant Projects, H1 2016 79
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.